Table 3.

Salient data of studies of DPP4 inhibitors in hospitalized patients with T2D

References	Design	Patients and treatment	Main findings
Umpierrez (2013) [66]	Pilot randomized study	90 in-patients; sitagliptin alone or combined with glargine or a basal-bolus (glargine and lispro) both with correctional insulin doses	No differences in glycemic control, length of hospital stay and hypoglycemia events Fewer total daily insulin doses and numbers of insulin injections in sitagliptin groups
Pasquel (2017) [67]	Non-inferiority randomized-controlled trial	277 in-patients; sitagliptin plus basal glargine once daily or basal-bolus (glargine and lispro) both with correctional insulin doses	Mean daily glucose concentration was non-inferior No differences in hospital complications, length of stay, hypoglycemic events and treatment failures
Garg (2017) [68]	Randomized-controlled trial	66 in-patients; saxagliptin or basal-bolus insulin therapy, both with correctional insulin doses	Non-inferior in mean daily blood glucose control  Lower glycemic variability  Basal-bolus insulin: higher number of injections and daily insulin dose